The retina contains two main types of photoreceptor cells: rods, which are responsible for vision in low-light conditions, and cones, which support daylight and color vision. In dogs affected by CNGA1-PRA, these photoreceptor cells gradually lose their ability to respond to light. Rod cells are typically affected first, resulting in early difficulties with night vision. As the disease progresses, cone cells also degenerate, causing increasing impairment of daytime vision.
One of the earliest signs of CNGA1-PRA is night blindness, where dogs may appear hesitant to move in dimly lit environments or have difficulty navigating after sunset. Owners may notice their dog bumping into furniture, missing steps, or showing reluctance to enter dark areas. As retinal degeneration advances, vision loss becomes more noticeable during daylight hours. Dogs may struggle to recognize obstacles, locate toys, or confidently move through unfamiliar surroundings. In the later stages of the disease, complete blindness can occur. Although CNGA1-PRA leads to significant visual impairment, it is generally not painful, and many affected dogs adapt well with proper care and environmental support.
The CNGA1-PRA DNA Health Test is designed to detect the specific genetic mutation associated with this form of Progressive Retinal Atrophy. Testing is simple, safe, and non-invasive, typically requiring either a cheek swab or blood sample. The sample is analyzed in a specialized laboratory to determine whether the dog carries the CNGA1 mutation. Since the test evaluates DNA directly, it can be performed at any age, including in puppies before symptoms develop.
Test results are generally reported in one of three categories:
- Clear (Normal): The dog does not carry the CNGA1-PRA mutation and cannot pass it to offspring.
- Carrier: The dog carries one copy of the mutation but is not expected to develop the disease. However, it can pass the mutation to future generations.
- Affected/At Risk: The dog carries two copies of the mutation and has a high likelihood of developing CNGA1-related Progressive Retinal Atrophy during its lifetime.
Genetic testing for CNGA1-PRA provides valuable information for breeders, veterinarians, and dog owners. Breeders can use the results to make informed breeding decisions that help reduce the prevalence of the disease while preserving genetic diversity within the breed. Careful breeding management can significantly decrease the risk of producing affected puppies.
For pet owners, understanding a dog's genetic status allows for proactive eye health monitoring and regular veterinary ophthalmic examinations. While there is currently no cure for CNGA1-PRA, early identification enables owners to prepare for future vision changes and make lifestyle adjustments that help maintain a high quality of life for affected dogs.
The Progressive Retinal Atrophy (CNGA1-PRA) Health Test is a reliable genetic screening tool that supports responsible breeding, promotes canine eye health, and helps reduce the impact of inherited blindness. Through early detection and informed breeding strategies, breeders and owners can contribute to healthier future generations of dogs and improved long-term welfare.
